Literature DB >> 1738706

Total hip arthroplasty for protrusio acetabuli: a 3- to 9-year follow up of the Heywood technique.

F R Ebert1, S Hussain, K A Krackow.   

Abstract

Thirty-five total joint arthroplasties (34 patients) were performed in patients who had protrusio acetabuli. Twenty-nine percent of the patients had acetabular protrusio of grade I, while 71% had grade II and grade III protrusio. The mean follow up was 4 years (range: 3 to 9). Cemented acetabular components were used in 11 hips; 24 hips received an uncemented porous coated acetabular component. The patient evaluations included preoperative and postoperative Harris Hip Ratings and standard radiographs. In all cases, the medial wall defect was reconstructed with the solid autogenous femoral head as described by Heywood. The mean preoperative Harris Hip Rating was 45 (range: 30 to 60 points), and the postoperative mean was 85 (range: 70 to 100 points). Radiographically, the preoperative protrusio measured a mean of 8.8 mm (range: 6 to 18 mm), and the mean postoperative placement of the femoral head was 10 mm lateral to Kohler's line (range: 6 to 13 mm). There were no acetabular component failures and no acetabular bone graft resorptions. All autogenous grafts were incorporated to the host radiographically by 1 year post-surgery. This study corroborates previous work which suggests that medial-placed bone grafting is not resorbed and consolidates with the host bone. We find this technique extremely useful in dealing with this technical problem.

Entities:  

Mesh:

Year:  1992        PMID: 1738706     DOI: 10.3928/0147-7447-19920101-06

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  1 in total

1.  Long-term results of the uncemented acetabular component in a primary total hip arthroplasty performed for protrusio acetabuli: a fifteen year median follow-up.

Authors:  Yaser M K Baghdadi; A Noelle Larson; Rafael J Sierra
Journal:  Int Orthop       Date:  2014-11-09       Impact factor: 3.075

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.